HBM7004 / Harbour BioMed - LARVOL DELTA

Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors (Yahoo Finance) - "The development of HBM7004 further demonstrated the HBICE platform's versatility and plug-and-play advantages. In preclinical studies, HBM7004 demonstrated an intratumor B7H4-dependent T cell activation manner. In multiple animal models, HBM7004 showed strong anti-tumor efficacy, remarkable in vivo stability, and reduced systemic toxicity. Additionally, in preclinical models, HBM7004 exhibited a strong synergistic effect when combined with a B7H4x4-1BB bispecific antibody at a low effector-to-target cell ratio, indicating an encouraging therapeutic window."

New trial • Preclinical • Solid Tumor

Harbour BioMed Announces NMPA Acceptance of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors (PRNewswire)

New trial • Solid Tumor

HBM HOLDINGS-B…announced that it has obtained approval from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application and will initiate a first-in-human Phase I clinical trial in the United States for its novel B7H4xCD3 bispecific antibody HBM7004. (iis.aastocks.com) - "The Phase I study will evaluate the safety, tolerability, pharmacokinetic profile and preliminary anti-tumor activity of HBM7004 in patients with advanced solid tumors."

IND • New P1 trial • Solid Tumor

Harbour BioMed Reports Full Year 2022 Financial Results (PRNewswire) - "In addition, HBM7022 (CLDN18.2xCD3), HBM7004 (B7H4x4-1BB), HBM9027 (PD-L1xCD40), HBM9033 (MSLN ADC), HBM1047 (CD200R1) and HBM9014 (LIFR) are all preclinical stage products in the company's pipeline. With the efficient output of the technology platforms as well as the rich expertise of our R&D team, the Company aims to file at least one IND each year moving forward."

IND • Oncology • Solid Tumor

HBM7008 (B7H4x4-1BB HBICE) Synergizes HBM7004 (B7H4xCD3 HBICE) for Solid Tumor Therapy (SITC 2022) - "Ethics Approval The cancer tissue microarray was purchased from Fanpu Biotech, Inc. The company ensured ethical approval from the patients, and patient consent for publication."

IO biomarker • Hematological Malignancies • Oncology • Solid Tumor • HER-2 • TNFRSF9 • VTCN1